Vancouver's large Chinese, Vietnamese, and Korean communities — from countries with among the world's highest Hepatitis B prevalence — create significant long-term HBV treatment demand across BC Health and private hepatology clinics. Tafsure provides Vancouver's HBV patients with the most advanced TAF-based treatment at significantly reduced cost, with superior kidney and bone safety over older TDF alternatives.
Unnati Pharmax ships to Vancouver and across British Columbia. Visit unnatipharmax.com or WhatsApp +91 82650 41513 or email Unnatipharmax@gmail.com.
FAQ 1: What is the difference between TAF (Tafsure) and TDF (Tavin) for Hepatitis B treatment?Both TAF (Tenofovir Alafenamide — Tafsure) and TDF (Tenofovir Disoproxil Fumarate — Tavin) are prodrugs that convert to the same active compound inside cells and have essentially identical antiviral efficacy against Hepatitis B. The critical difference is in delivery mechanism. TDF releases active Tenofovir into the bloodstream at high concentrations — effective but causing kidney and bone toxicity. TAF is an improved prodrug engineered to deliver Tenofovir directly inside liver cells (the HBV target) at much lower systemic concentrations — achieving the same antiviral suppression with 89% lower plasma drug levels. The clinical result: Tafsure produces no significant kidney function decline and no bone density loss compared to TDF, making it the preferred HBV treatment for Vancouver patients with any kidney, bone, or metabolic concerns. FAQ 2: How often should HBV viral load (HBV DNA) be tested while on Tafsure?Standard HBV DNA monitoring on Tafsure follows this schedule: at baseline before starting (to establish the pre-treatment viral load), then at 12 weeks and 24 weeks to assess initial response, then every 6 months once viral suppression is confirmed. Most patients achieve undetectable HBV DNA (below 20 IU/mL) within 48 weeks of Tafsure therapy. Liver function tests (ALT, AST) are checked at the same intervals. Additional monitoring includes annual HBsAg quantification — a gradual decline in HBsAg levels over years of treatment predicts who might eventually achieve the rare functional cure (HBsAg loss). Vancouver's hepatology teams at VGH adjust monitoring frequency based on individual response and fibrosis stage. FAQ 3: Can Tafsure be taken during breastfeeding?TAF (Tafsure) is excreted in breast milk at low concentrations. The clinical significance for breastfed infants is uncertain — limited data exists on infant exposure through breast milk and potential effects. Current WHO and Canadian guidelines do not definitively contraindicate breastfeeding during TAF therapy, but caution is advised. For Vancouver mothers with chronic Hepatitis B requiring ongoing antiviral therapy, a discussion with their hepatologist and a paediatrician is recommended to weigh the benefits of breastfeeding against theoretical infant exposure risk. TDF (Tavin) has a longer track record in breastfeeding safety data and is currently preferred where maternal antiviral therapy during breastfeeding is required. FAQ 4: What Hepatitis B vaccination schedule is recommended for unvaccinated family members of Tafsure users?Unvaccinated household contacts and sexual partners of HBsAg-positive individuals should receive the standard 3-dose Hepatitis B vaccine series as soon as possible — doses at 0, 1, and 6 months. In Canada, this vaccine is provided free through provincial immunisation programmes for household contacts of HBV-positive individuals in BC. A post-vaccination serology check (anti-HBs level) 4-8 weeks after the third dose confirms protective immunity. For non-responders (approximately 5-10% of vaccinees who don't develop adequate anti-HBs), a repeat 3-dose series is recommended. Sexual partners should also undergo HBsAg and anti-HBs testing before or simultaneously with vaccination to determine their current infection and immunity status. FAQ 5: Does Tafsure prevent liver cancer (hepatocellular carcinoma) in HBV patients?Long-term viral suppression with TAF (Tafsure) significantly reduces but does not eliminate the risk of hepatocellular carcinoma (HCC). Studies consistently show that sustained HBV suppression reduces HCC risk by 50-80% compared to untreated HBV. However, the risk is not zero — particularly in patients who already have liver cirrhosis at the time they start treatment, or those who experienced prolonged high viral loads before starting therapy. This is why Vancouver's hepatologists continue 6-monthly liver ultrasound surveillance for HCC in all HBV-positive patients with cirrhosis even after viral suppression is achieved on Tafsure. In non-cirrhotic patients with sustained suppression, surveillance intervals may be extended, though some centres continue surveillance for all HBsAg-positive individuals regardless of fibrosis stage given the residual risk.